MétaCan
Menu
Back to cohort
Record W1984405988 · doi:10.1016/j.bbmt.2011.12.317

Dose, Schedule and PK Practices with IV Busulfan-Based Conditioning Regimens in a Non-Inferiority Study: Heterogenous Practices But Low VOD and TRM

2012· article· en· W1984405988 on OpenAlexaff
Christopher Bredeson, Jeanne Burkart, Yongliang Sun, Xiaochun Zhu, Jennifer Le‐Rademacher, J. Douglas Rizzo, Elizabeth Armstrong, Marcelo C. Pasquini, Kanae Kato

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2012
Typearticle
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsOttawa Hospital
Fundersnot available
KeywordsMedicineBusulfanDosingInternal medicineRegimenCyclophosphamideSurgeryGastroenterologyChemotherapy

Abstract

fetched live from OpenAlex

The CIBMTR is conducting a non-inferiority study of myeloablative IV busulfan-based conditioning regimens vs. traditional ablative cyclophosphamide and TBI in patients (pts) with myeloid malignancies undergoing related or unrelated SCT to compare overall survival between regimens. Accrual is complete with 477 pts conditioned with CyTBI and 1273 with IV busulfan-based regimens from 120 centers. We report initial data regarding busulfan (BU) dosing and PK practices. Of 1273 pts receiving IV BU, the regimen was ablative in 1118 and reduced intensity in 155. Donors were related (507 pts) or unrelated (766 pts). Diagnosis was AML (791 pts), MDS (365 pts), CML (117 pts). Graft source was BM (272 pts) or PB (1001 pts). Median age was 47 (1-61) yrs and 52% of pts were male. The majority (66%) had a performance score of 90-100. GVHD prophylaxis for all pts was a calcineurin inhibitor of tacrolimus (1035 pts) or cyclosporine (238 pts) +/- other agents. BU dosing was most commonly Q6H followed by daily. The vast majority of pts received 4 days of BU (95%), including about half of the RIC group. Approximately half of both related and unrelated SCT recipients underwent PK testing. Most PK testing was done with the first dose of conditioning (80.6%), the remainder as a preceding test dose. Dose adjustment was planned for nearly all pts receiving ablative regimens that underwent PK testing (98%) and in a minority of RIC pts (8%). BU was targeted based on AUC in 63.5%; the remainder with CSS. Some centers used both AUC and CSS for PK testing. Most pts' subsequent BU dose (77.6%) was adjusted in response to PK results including 5 RIC pts. The incidence of VOD at 100 days for all pts receiving IV busulfan-based conditioning was 5% (4%-7%) and was similar in pts receiving ablative or RIC. In 889 pts with data available, the cumulative incidence of TRM at 100 days and 6 months was 8% (6%-10%) and 12% (10%-14%). Practices regarding BU dosing and schedules and the use of PK testing with IV busulfan-based conditioning vary within and between centers. In a large prospective observational study, IV busulfan-based conditioning regimens appear safe with a low incidence of VOD and TRM in a group of pts receiving both related and unrelated transplants. Results from the comparative study after 1 year of follow up will address the safety and efficacy of IV busulfan-based conditioning regimens compared to CyTBI.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.018
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.018
Threshold uncertainty score0.096

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0180.009
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.321
Teacher spread0.297 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicAcute Myeloid Leukemia ResearchFrench-language works237,207